• 1. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219
• 2. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 3. An amphoteric reactivity of a mixed-valent bis(μ-oxo)dimanganese(iii,iv) complex acting as an electrophile and a nucleophile?
  Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383
• 4. An insight into the origin of room-temperature ferromagnetism in SnO2 and Mn-doped SnO2 quantum dots: an experimental and DFT approach?
  Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514
• 5. An approach for correlating the structural and electrical properties of Zr4+-modified SrBi4Ti4O15/SBT ceramic
  Priyambada Nayak,Tanmaya Badapanda,Anil Kumar Singh,Simanchalo Panigrahi RSC Adv., 2017,7, 16319-16331

Recent Advances in the Study of 1-Piperazineethanamine, 4,4'-(1,2-ethanediyl)bis- (CAS: 127723-05-1)

The compound 1-Piperazineethanamine, 4,4'-(1,2-ethanediyl)bis-, with the CAS number 127723-05-1, has garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. Recent studies have explored its role as a versatile building block in drug discovery, particularly in the development of novel small-molecule inhibitors and modulators for various biological targets. This research brief aims to summarize the latest findings related to this compound, highlighting its synthetic utility, mechanistic insights, and emerging applications in biomedicine.

One of the key areas of investigation has been the compound's ability to serve as a bifunctional linker in the design of polypharmacological agents. Researchers have leveraged its symmetrical piperazine-ethane backbone to create hybrid molecules that simultaneously target multiple pathways involved in diseases such as cancer and neurodegenerative disorders. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that derivatives of 127723-05-1 exhibited potent dual inhibition of HDAC and PI3K enzymes, showing promising anti-proliferative effects in vitro and in vivo models of breast cancer.

In addition to its pharmacological applications, recent work has focused on optimizing the synthetic routes for 1-Piperazineethanamine, 4,4'-(1,2-ethanediyl)bis-. A team at MIT developed a novel catalytic system that improved the yield and purity of the compound while reducing environmental impact. Their green chemistry approach, published in ACS Sustainable Chemistry & Engineering, represents an important step forward in the scalable production of this valuable intermediate for pharmaceutical manufacturing.

Structural biology studies have provided new insights into the molecular interactions of this compound with biological targets. Cryo-EM and X-ray crystallography data revealed that the ethylene-bridged piperazine moiety enables unique binding conformations that enhance target engagement and selectivity. These findings, reported in Nature Chemical Biology, have important implications for rational drug design using this scaffold.

Emerging applications in radiopharmaceuticals have also been explored, with 127723-05-1 serving as a chelating agent for diagnostic and therapeutic radioisotopes. A recent clinical trial demonstrated the potential of its technetium-99m conjugate as a novel PET imaging probe for tumor detection, showing superior pharmacokinetic properties compared to existing agents.

While the therapeutic potential of this compound class is significant, challenges remain in optimizing drug-like properties such as metabolic stability and blood-brain barrier penetration. Ongoing structure-activity relationship studies aim to address these limitations while maintaining the beneficial pharmacological profile of the parent scaffold.

In conclusion, 1-Piperazineethanamine, 4,4'-(1,2-ethanediyl)bis- (127723-05-1) continues to be a valuable tool in medicinal chemistry, with recent advances expanding its applications across multiple therapeutic areas. The compound's versatility as a molecular scaffold, combined with improved synthetic methods and deeper mechanistic understanding, positions it as an important focus for future drug discovery efforts.

• 109-01-3(1-Methylpiperazine)
• 934-98-5(2-(4-methylpiperazin-1-yl)ethan-1-amine)
• 24426-16-2(N,N-Diethyldiethylenetriamine)
• 3030-47-5(1,1,4,7,7-Pentamethyldiethylenetriamine)
• 6531-38-0(1,4-Piperazinediethylamine)
• 5308-25-8(1-Ethylpiperazine)
• 4097-89-6(Tris(2-aminoethyl)amine)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)